Advertisement

Interstitial Cystitis/Bladder Pain Syndrome

  • Paul K. ChengEmail author
  • Tariq Malik
Chapter
  • 47 Downloads

Abstract

Interstitial cystitis or bladder pain syndrome is a chronic condition of suprapubic pain associated with bladder distention and accompanied by lower urinary tract symptoms such as urgency, frequency, and nocturia. Commonly affecting those in the fourth and fifth decades with a strong preponderance for female gender, IC has a complex and poorly understood pathophysiology which involves urothelial dysfunction, inflammatory disturbances, neuroendocrine changes, and central sensitization. The mainstays of treatment include patient education, diet and activity modification, and physical therapy as well as both oral and intravesicular therapies. Common oral pharmacologic agents include amitriptyline, hydroxyzine, cimetidine, pentosan polysulfate, and cyclosporine, while common intravesicular therapies include heparin, lidocaine, hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dimethyl sulfoxide, triamcinolone, and botulinum toxin A. For patients not responsive to more-conservative therapies, a host of interventions and surgeries can be done including cystoscopy and fulguration of ulcerative lesions, neuromodulation, and cystectomy. Current research involves discovery of biomarkers to aid in diagnosis of IC as well as development of both oral and intravesicular therapies aimed at providing greater relief to those suffering from BPS.

Keywords

Interstitial cystitis Bladder pain syndrome Urinary tract Intravesicular Hunner’s lesions 

References

  1. 1.
    Douglas-Moore JL, Goddard J. Current best practice in the management of cystitis and pelvic pain. Ther Adv Urol. 2018;10(1):17–22.CrossRefGoogle Scholar
  2. 2.
    Goddard J. Cystitis and pelvic pain management: guidelines versus real-world practice. Urologia. 2017;84(Suppl 1):1–4.CrossRefGoogle Scholar
  3. 3.
    Patnaik SS, Lagana AS, Vitale SG, Buttice S, Noventa M, Gizzo S, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet. 2017;295(6):1341–59.CrossRefGoogle Scholar
  4. 4.
    Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–70.CrossRefGoogle Scholar
  5. 5.
    McLennan MT. Interstitial cystitis: epidemiology, pathophysiology, and clinical presentation. Obstet Gynecol Clin N Am. 2014;41(3):385–95.CrossRefGoogle Scholar
  6. 6.
    Tamaki M, Saito R, Ogawa O, Yoshimura N, Ueda T. Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors. J Urol. 2004;172(3):945–8.CrossRefGoogle Scholar
  7. 7.
    Fall M, Logadottir Y, Peeker R. Interstitial cystitis is bladder pain syndrome with Hunner’s lesion. Int J Urol. 2014;21 Suppl 1:79–82.CrossRefGoogle Scholar
  8. 8.
    Chrysanthopoulou EL, Doumouchtsis SK. Challenges and current evidence on the management of bladder pain syndrome. Neurourol Urodyn. 2014;33(8):1193–201.CrossRefGoogle Scholar
  9. 9.
    Meng E, Hsu YC, Chuang YC. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Low Urin Tract Symptoms. 2018;10(1):3–11.CrossRefGoogle Scholar
  10. 10.
    Ha T, Xu JH. Interstitial cystitis intravesical therapy. Transl Androl Urol. 2017;6(Suppl 2):S171–S9.CrossRefGoogle Scholar
  11. 11.
    Jhang JF, Wu SY, Lin TY, Kuo HC. Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. Low Urin Tract Symptoms. 2019;11(2):O42–7.CrossRefGoogle Scholar
  12. 12.
    Wang J, Chen Y, Chen J, Zhang G, Wu P. Sacral neuromodulation for refractory bladder pain syndrome/interstitial cystitis: a global systematic review and meta-analysis. Sci Rep. 2017;7(1):11031.CrossRefGoogle Scholar
  13. 13.
    Tirlapur SA, Vlismas A, Ball E, Khan KS. Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review. Acta Obstet Gynecol Scand. 2013;92(8):881–7.CrossRefGoogle Scholar
  14. 14.
    Lee MH, Chang KM, Tsai WC. Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome. Int Urogynecol J. 2018;29(7):1045–50.CrossRefGoogle Scholar
  15. 15.
    Lusty A, Kavaler E, Zakariasen K, Tolls V, Nickel JC. Treatment effectiveness in interstitial cystitis/bladder pain syndrome: do patient perceptions align with efficacy-based guidelines? Can Urol Assoc J. 2018;12(1):E1–5.CrossRefGoogle Scholar
  16. 16.
    Andersson KE, Birder L. Current pharmacologic approaches in painful bladder research: an update. Int Neurourol J. 2017;21(4):235–42.CrossRefGoogle Scholar
  17. 17.
    Kim JH, Kim E, Kim BI. Pulsed radiofrequency treatment of the superior hypogastric plexus in an interstitial cystitis patient with chronic pain and symptoms refractory to oral and intravesical medications and bladder hydrodistention: a case report. Medicine (Baltimore). 2016;95(49):e5549.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Anesthesiology and Pain MedicineUC Davis Medical CenterSacramentoUSA
  2. 2.Department of Anesthesia and Critical CareUniversity of ChicagoChicagoUSA

Personalised recommendations